期刊
NATURE CELL BIOLOGY
卷 23, 期 11, 页码 1187-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41556-021-00781-z
关键词
-
类别
资金
- Breast Cancer Research Foundation [BCRF-21-019]
- Ludwig Center at Harvard
The study reveals an epigenetic mechanism leading to adaptive resistance of triple-negative breast cancer to FGFR inhibitors, involving suppression of chromatin remodeling function, derepression of YAP-associated enhancers, and upregulation of amino acid-induced mTORC1 activity. Combining mTORC1 or YAP inhibitors with FGFR blockade synergistically attenuates the growth of TNBC patient-derived xenograft models, providing potential therapeutic strategies to overcome this mechanism of resistance.
How cancer cells adapt to evade the therapeutic effects of drugs targeting oncogenic drivers is poorly understood. Here we report an epigenetic mechanism leading to the adaptive resistance of triple-negative breast cancer (TNBC) to fibroblast growth factor receptor (FGFR) inhibitors. Prolonged FGFR inhibition suppresses the function of BRG1-dependent chromatin remodelling, leading to an epigenetic state that derepresses YAP-associated enhancers. These chromatin changes induce the expression of several amino acid transporters, resulting in increased intracellular levels of specific amino acids that reactivate mTORC1. Consistent with this mechanism, addition of mTORC1 or YAP inhibitors to FGFR blockade synergistically attenuated the growth of TNBC patient-derived xenograft models. Collectively, these findings reveal a feedback loop involving an epigenetic state transition and metabolic reprogramming that leads to adaptive therapeutic resistance and provides potential therapeutic strategies to overcome this mechanism of resistance. Li et al. define an adaptive resistance mechanism against FGFR inhibitor treatment in breast cancer attributed to loss of BRG1 chromatin recruitment, reactivation of YAP-dependent enhancers and upregulation of amino acid-induced mTORC1 activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据